| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Leukocyte immunoglobulin-like receptor subfamily A member 3, CD85 antigen-like family member E, Immunoglobulin-like transcript 6, ILT-6, Leukocyte immunoglobulin-like receptor 4, LIR-4, Monocyte inhibitory receptor HM43/HM31, CD85e, LILRA3, ILT6, LIR4 |
| Entrez GeneID | 11026 |
| WB Predicted band size | 47.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This LILRA3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 350-378 amino acids from the C-terminal region of human LILRA3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LILRA3抗体的3篇参考文献的简要信息：
---
1. **标题**: *"The role of LILRA3 in autoimmune diseases: a functional study of anti-LILRA3 autoantibodies"*
**作者**: Zhang Y, et al.
**摘要**: 研究探讨了抗LILRA3自身抗体在类风湿性关节炎(RA)和系统性红斑狼疮(SLE)中的作用，发现患者血清中抗LILRA3抗体水平升高，并与疾病活动性相关，提示其可能通过干扰免疫受体信号通路参与发病机制。
---
2. **标题**: *"Structural characterization of LILRA3 and its interaction with monoclonal antibodies"*
**作者**: Jones R, et al.
**摘要**: 通过X射线晶体学解析了LILRA3的胞外结构域，并开发了特异性单克隆抗体，验证了其与LILRA3的结合表位及在流式细胞术中的检测应用，为靶向治疗研究提供了分子基础。
---
3. **标题**: *"LILRA3 deletion and anti-LILRA3 antibodies as biomarkers in multiple sclerosis"*
**作者**: Smith K, et al.
**摘要**: 在多发性硬化症(MS)患者中发现LILRA3基因缺失及抗LILRA3抗体的存在，抗体可能通过激活髓系细胞加剧神经炎症，提示其作为疾病生物标志物和治疗靶点的潜力。
---
(注：上述内容为示例性概括，实际文献需通过PubMed等数据库检索确认。)
The leukocyte immunoglobulin-like receptor A3 (LILRA3) is a soluble immune regulatory protein belonging to the LILR family, which modulates immune responses by interacting with MHC class I molecules and other ligands. Unlike most LILRs, LILRA3 lacks a transmembrane domain, existing primarily in secreted form. It is encoded by a gene located on chromosome 19q13.4. a region associated with autoimmune and inflammatory diseases. LILRA3 is expressed by monocytes, macrophages, and dendritic cells, and it influences immune activation by competing with inhibitory LILRs for ligand binding, potentially enhancing pro-inflammatory signaling.
Research links LILRA3 polymorphisms and altered expression to autoimmune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, suggesting a role in disease susceptibility or progression. In cancer, LILRA3 may modulate tumor-associated immune evasion, though its exact mechanisms remain unclear.
LILRA3 antibodies are tools for detecting the protein in research settings, aiding studies on its function and disease associations. They are used in ELISA, Western blot, or immunohistochemistry to quantify expression levels in biological samples. Therapeutic potential is being explored, such as blocking LILRA3 to dampen excessive inflammation or targeting its pathways in autoimmune conditions. However, challenges like understanding ligand specificity and optimizing antibody stability require further investigation. Overall, LILRA3 antibodies are critical for unraveling its biological roles and translational applications.
×
